Superior Bioavailability of a Novel Curcumin Formulation in Healthy Humans Under Fasting Conditions

Kothaplly S, Alukapally S, Nagula N, Maddela R · Advances in Therapy

Reported Cmax about 100-fold and AUC0-6 about 144-149-fold higher than the turmeric extract comparator, with 40% faster absorption.

Population

Healthy volunteers, randomized double-blind three-treatment crossover, India (CTRI/2020/10/028508)

Intervention

Curcuwin Ultra+ 250 mg or 500 mg

Comparator

95% turmeric extract 1900 mg

Limitations

Funded by OmniActive Health Technologies, which supplied both the test product and the comparator, with authors from a contract research organisation; 23 of 24 completed. The three-figure multiplier is dose-normalised (250 mg against 1,900 mg) and measured after enzymatic deconjugation, the kind of figure that pmid-34665507 and pmid-40487425 identify as the field's central measurement problem. Single dose, no clinical endpoint.